@article{DorenkampBoldtLeberetal.2013, author = {Dorenkamp, Marc and Boldt, Julia and Leber, Alexander W. and Sohns, Christian and Roser, Mattias and Boldt, Leif-Hendrik and Haverkamp, Wilhelm and Bonaventura, Klaus}, title = {Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis}, series = {Clinical cardiology : international journal for cardiovascular diseases}, volume = {36}, journal = {Clinical cardiology : international journal for cardiovascular diseases}, number = {7}, publisher = {Wiley-Blackwell}, address = {Hoboken}, issn = {0160-9289}, doi = {10.1002/clc.22130}, pages = {407 -- 413}, year = {2013}, abstract = {BackgroundThe economic impact of drug-eluting stent (DES) in-stent restenosis (ISR) is substantial, highlighting the need for cost-effective treatment strategies. HypothesisCompared to plain old balloon angioplasty (POBA) or repeat DES implantation, drug-coated balloon (DCB) angioplasty is a cost-effective therapy for DES-ISR. MethodsA Markov state-transition model was used to compare DCB angioplasty with POBA and repeat DES implantation. Model input parameters were obtained from the literature, and the cost analysis was conducted from a German healthcare payer's perspective. Extensive sensitivity analyses were performed. ResultsInitial procedure costs amounted to Euro3488 for DCB angioplasty and to Euro2782 for POBA. Over a 6-month time horizon, the DCB strategy was less costly (Euro4028 vs Euro4169) and more effective in terms of life-years (LYs) gained (0.497 versus 0.489) than POBA. The DES strategy incurred initial costs of Euro3167 and resulted in 0.494 LYs gained, at total costs of Euro4101 after a 6-month follow-up. Thus, DCB angioplasty was the least costly and most effective strategy. Base-case results were influenced mostly by initial procedure costs, target lesion revascularization rates, and the costs of dual antiplatelet therapy. ConclusionsDCB angioplasty is a cost-effective treatment option for coronary DES-ISR. The higher initial costs of the DCB strategy compared to POBA or repeat DES implantation are offset by later cost savings.}, language = {en} } @article{MayerBonaventuraCasseletal.2012, author = {Mayer, Frank and Bonaventura, Klaus and Cassel, Michael and M{\"u}ller, Steffen and Weber, Josefine and Scharhag-Rosenberger, Friederike and Carlsohn, Anja and Baur, Heiner and Scharhag, J{\"u}rgen}, title = {Medical results of preparticipation examination in adolescent athletes}, series = {British journal of sports medicine : the journal of sport and exercise medicine}, volume = {46}, journal = {British journal of sports medicine : the journal of sport and exercise medicine}, number = {7}, publisher = {BMJ Publ. Group}, address = {London}, issn = {0306-3674}, doi = {10.1136/bjsports-2011-090966}, pages = {524 -- 530}, year = {2012}, abstract = {Background Preparticipation examinations (PPE) are frequently used to evaluate eligibility for competitive sports in adolescent athletes. Nevertheless, the effectiveness of these examinations is under debate since costs are high and its validity is discussed controversial. Purpose To analyse medical findings and consequences in adolescent athletes prior to admission to a sports school. Methods In 733 adolescent athletes (318 girls, 415 boys, age 12.3+/-0.4, 16 sports disciplines), history and clinical examination (musculoskeletal, cardiovascular, general medicine) was performed to evaluate eligibility. PPE was completed by determination of blood parameters, ECG at rest and during ergometry, echocardiography and x-rays and ultrasonography if indicated. Eligibility was either approved or rated with restriction. Recommendations for therapy and/or prevention were given to the athletes and their parents. Results Historical (h) and clinical (c) findings (eg, pain, verified pathologies) were more frequent regarding the musculoskeletal system (h: 120, 16.4\%; c: 247, 33.7\%) compared to cardiovascular (h: 9, 1.2\%; c: 23, 3.1\%) or general medicine findings (h: 116, 15.8\%; c: 71, 9.7\%). ECG at rest was moderately abnormal in 46 (6.3\%) and severely abnormal in 25 athletes (3.4\%). Exercise ECG was suspicious in 25 athletes (3.4\%). Relevant echocardiographic abnormalities were found in 17 athletes (2.3\%). In 52 of 358 cases (14.5\%), x-rays led to diagnosis (eg, Spondylolisthesis). Eligibility was temporarily restricted in 41 athletes (5.6\%). Three athletes (0.4\%) had to be excluded from competitive sports. Therapy (eg, physiotherapy, medication) and/or prevention (sensorimotor training, vaccination) recommendations were deduced due to musculoskeletal (t:n = 76,10.3\%; p:n = 71,9.8\%) and general medicine findings (t:n = 80, 10.9\%; p:n = 104, 14.1\%). Conclusion Eligibility for competitive sports is restricted in only 5.5\% of adolescent athletes at age 12. Eligibility refusals are rare. However, recommendations for therapy and prevention are frequent, mainly regarding the musculoskeletal system. In spite of time and cost consumption, adolescent preparticipation before entering a career in high-performance sports is supported.}, language = {en} } @article{SchraplauBlockHaeusleretal.2021, author = {Schraplau, Anne and Block, Andrea and H{\"a}usler, Andreas and Wippert, Pia-Maria and Rapp, Michael A. and V{\"o}ller, Heinz and Bonaventura, Klaus and Mayer, Frank}, title = {Mobile diagnostics and consultation for the prevention of the metabolic syndrome and its secondary diseases in Brandenburg—study protocol of a regional prospective cohort study}, series = {Pilot and Feasibility Studies}, volume = {7}, journal = {Pilot and Feasibility Studies}, publisher = {BioMed Central (Springer Nature)}, address = {London}, issn = {2055-5784}, doi = {10.1186/s40814-021-00898-w}, pages = {1 -- 11}, year = {2021}, abstract = {Background The metabolic syndrome (MetS) is a risk cluster for a number of secondary diseases. The implementation of prevention programs requires early detection of individuals at risk. However, access to health care providers is limited in structurally weak regions. Brandenburg, a rural federal state in Germany, has an especially high MetS prevalence and disease burden. This study aims to validate and test the feasibility of a setup for mobile diagnostics of MetS and its secondary diseases, to evaluate the MetS prevalence and its association with moderating factors in Brandenburg and to identify new ways of early prevention, while establishing a "Mobile Brandenburg Cohort" to reveal new causes and risk factors for MetS. Methods In a pilot study, setups for mobile diagnostics of MetS and secondary diseases will be developed and validated. A van will be equipped as an examination room using point-of-care blood analyzers and by mobilizing standard methods. In study part A, these mobile diagnostic units will be placed at different locations in Brandenburg to locally recruit 5000 participants aged 40-70 years. They will be examined for MetS and advice on nutrition and physical activity will be provided. Questionnaires will be used to evaluate sociodemographics, stress perception, and physical activity. In study part B, participants with MetS, but without known secondary diseases, will receive a detailed mobile medical examination, including MetS diagnostics, medical history, clinical examinations, and instrumental diagnostics for internal, cardiovascular, musculoskeletal, and cognitive disorders. Participants will receive advice on nutrition and an exercise program will be demonstrated on site. People unable to participate in these mobile examinations will be interviewed by telephone. If necessary, participants will be referred to general practitioners for further diagnosis. Discussion The mobile diagnostics approach enables early detection of individuals at risk, and their targeted referral to local health care providers. Evaluation of the MetS prevalence, its relation to risk-increasing factors, and the "Mobile Brandenburg Cohort" create a unique database for further longitudinal studies on the implementation of home-based prevention programs to reduce mortality, especially in rural regions. Trial registration German Clinical Trials Register, DRKS00022764; registered 07 October 2020—retrospectively registered.}, language = {en} }